Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133)
Makoto Nishio(Japanese Foundation For Cancer Research), Tomohisa Kawakami, Hiroshi Sakai(Hiroshima University), Shinji Atagi(National Institute of Technology, Nara College), Isamu Okamoto(Kyushu University Hospital), Yuki Nakagawa, Shunichi Sugawara(Sendai Kousei Hospital), Koichi Takayama(Kyoto Prefectural University of Medicine), Hiroaki Akamatsu(Army Medical University), Hidetoshi Hayashi(Kindai University)
Cited by 48
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k